DNA duplexes with hydrophobic modifications inhibit fusion between HIV-1 and cell membranes

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4963-4970

  Xu, Liang ^a   Cai, Lifeng ^a   Chen, Xueliang ^a,b   Jiang, Xifeng ^a   Chong, Huihui ^c   Zheng, Baohua ^a,b   Wang, Kun ^a   He, Junlin ^a   Chen, Wei ^a   Zhang, Tao ^a   Cheng, Maosheng ^b   He, Yuxian ^c   Liu, Keliang ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c INSTITUTE OF PATHOGEN BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; DOUBLE STRANDED DNA; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; NUCLEIC ACID BASE; OLIGODEOXYNUCLEOTIDE; REPETITIVE DNA;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; BASE PAIRING; CELL MEMBRANE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA HELIX; DNA MODIFICATION; DNA STRUCTURE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; IC 50; LIPID BILAYER; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; STRUCTURE ACTIVITY RELATION; VIRUS CELL INTERACTION;

CELL LINE; CELL MEMBRANE; CIRCULAR DICHROISM; DNA; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIV FUSION INHIBITORS; HIV-1; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIPID BILAYERS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84884224908     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00758-13     Document Type: Article

References (38)

1. Bhattacharya S, Osman H. 2009. Novel targets for anti-retroviral therapy. J. Infect. 59:377-386.
2. Turner JJ, Fabani M, Arzumanov AA, Ivanova G, Gait MJ. 2006. Targeting the HIV-1RNAleader sequence with synthetic oligonucleotides and siRNA: chemistry and cell delivery. Biochim. Biophys. Acta 1758: 290-300.
3. Weber ND, Merkel OM, Kissel T, Muñoz-Fernández MÁ. 2012. PEGylated poly(ethylene imine) copolymer-delivered siRNA inhibits HIV replication in vitro. J. Control Release 157:55- 63.
4. Zhou J, Shu Y, Guo P, Smith DD, Rossi JJ. 2011. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. Methods 54:284-294.
5. Moelling K, Abels S, Jendis J, Matskevich A, Heinrich J. 2006. Silencing of HIV by hairpin-loop-structured DNA oligonucleotide. FEBS Lett. 580: 3545-3550.
6. Michalowski D, Chitima-Matsiga R, Held DM, Burke DH. 2008. Novel bimodular DNA aptamers with guanosine quadruplexes inhibit phylogenetically diverse HIV-1 reverse transcriptases. Nucleic Acids Res. 36: 7124-7135.
7. Ferguson MR, Rojo DR, Somasunderam A, Thiviyannathan V, Ridley BD, Yang XB, Gorenstein DG. 2006. Delivery of double-stranded DNA thioaptamers into HIV-1 infected cells for antiviral activity. Biochem. Biophys. Res. Commun. 344:792-797.
8. Hannoush RN, Min KL, Damha MJ. 2004. Diversity-oriented solidphase synthesis and biological evaluation of oligonucleotide hairpins as HIV-1 RT RNase H inhibitors. Nucleic Acids Res. 32:6164-6175.
9. Katahira M, Kobayashi S, Matsugami A, Ouhashi K, Uesugi S, Yamamoto R, Taira K, Nishikawa S, Kumar P. 1999. Structural study of an RNA aptamer for a Tat protein complexed with ligands. Nucleic Acids Symp. Ser. 42:269-270.
10. Jing N, Marchand C, Liu J, Mitra R, Hogan ME, Pommier Y. 2000. Mechanism of inhibition of HIV-1 integrase by G-tetrad-forming oligonucleotides in vitro. J. Biol. Chem. 275:21460-21467.
11. Chou SH, Chin KH, Wang AH. 2005. DNA aptamers as potential anti- HIV agents. Trends Biochem. Sci. 30:231-234.
12. Kelley S, Boroda S, Musier-Forsyth K, Kankia BI. 2011. HIV-integrase aptamer folds into a parallel quadruplex: a thermodynamic study. Biophys. Chem. 155:82-88.
13. Mukundan VT, Do NQ, Phan AT. 2011. HIV-1 integrase inhibitor T30177 forms a stacked dimeric G-quadruplex structure containing bulges. Nucleic Acids Res. 39:8984-8991.
14. Wyatt JR, Vickers TA, Roberson JL, Buckheit RW, Jr, Klimkait T, DeBaets E, Davis PW, Rayner B, Imbach JL, Ecker DJ. 1994. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc. Natl. Acad. Sci. U. S. A. 91:1356-1360.
15. Zhou J, Swiderski P, Li H, Zhang J, Neff CP, Akkina R, Rossi JJ. 2009. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res. 37:3094-3109.
16. Hotoda H, Momota K, Furukawa H, Nakamura T, Kaneko M, Kimura S, Shimade K. 1994. Biologically active oligodeoxyribonucleotides-II: structure activity relationships of anti-HIV-1 pentadecadeoxyribonucleotides bearing 5=-end-modifications. Nucleosides Nucleotides Nucleic Acids 13:1375-1395.
17. Koizumi M, Koga R, Hotoda H, Momota K, Ohmine T, Furukawa H, Agatsuma T, Nishigaki T, Abe K, Kosaka T, Tsutsumi S, Sone J, Kaneko M, Kimura S, Shimada K. 1997. Biologically active oligodeoxyribonucleotides. IX. Synthesis and anti-HIV-1 activity of hexadeoxyribonucleotides, TGGGAG, bearing 3=and 5=-end-modification. Bioorg. Med. Chem. 5:2235-2243.
18. Hotoda H, Koizumi M, Koga R, Kaneko M, Momota K, Ohmine T, Furukawa H, Agatsuma T, Nishigaki T, Sone J, Tsutsumi S, Kosaka T, Abe K, Kimura S, Shimada K 5=-End-substituted d(TGGGAG) possesses anti-human immunodeficiency virus type 1 activity by forming a G-quadruplex structure. J. Med. Chem. 41:3655-3663.
19. D'Onofrio J, Petraccone L, Erra E, Martino L, Fabio GD, Napoli LD, Giancola C, Montesarchio D. 2007. 5=-Modified G-quadruplex forming oligonucleotides endowed with anti-HIV activity: synthesis and biophysical properties. Bioconjug Chem. 18:1194-1204.
20. Di Fabio G, D'Onofrio J, Chiapparelli M, Hoorelbeke B, Montesarchio D, Balzarini J, De Napoli L. 2011. Discovery of novel anti-HIV active G-quadruplex-forming oligonucleotides. Chem. Commun. 47:2363- 2365.
21. D'Onofrio J, Petraccone L, Martino L, Di Fabio G, Iadonisi A, Balzarini J, Giancola C, Montesarchio D. 2008. Synthesis, biophysical characterization, and anti-HIV activity of glyco-conjugated G-quadruplex-forming oligonucleotides. Bioconjug. Chem. 19:607-616.
22. Koizumi M, Akahori K, Ohmine T, Tsutsumi S, Sone J, Kosaka T, Kaneko M, Kimura S, Shimada K 2000. Biologically active oligodeoxyribonucleotides. Part. N2-methylation of 2=-deoxyguanosines enhances stability of parallel G-quadruplex and anti-HIV-1 activity. Bioorg. Med. Chem. Lett. 10:2213-2216.
23. Pedersen EB, Nielsen JT, Nielsen C, Filichev VV. 2011. Enhanced anti-HIV-1 activity of G-quadruplexes comprising locked nucleic acids and intercalating nucleic acids. Nucleic Acid Res. 39:2470-2481.
24. Koizumi M, Koga R, Hotoda H, Ohmine T, Furukawa H, Agatsuma T, Nishigaki T, Abe K, Kosaka T, Tsutsumi S, Sone J, Kaneko M, Kimura S, Shimada K.1998. Biologically active oligodeoxyribonucleotides. Part The least phosphate-modification of quadruplex-forming hexadeoxyribonucleotide TGGGAG, bearing 3-and 5-end-modification, with anti-HIV-1 activity. Bioorg. Med. Chem. 6:2469-2475.
25. Furukawa H, Momota K, Agatsuma T, Yamamoto I, Kimura S, Shimada K. 1994. Mechanism of inhibition of HIV-1 infection in vitro by guanine-rich oligonucleotides modified at the 5= terminal by dimethoxytrityl residue. Nucleic Acids Res. 22:5621-5627.
26. Agatsuma T, Yamamoto I, Furukawa H, Nishigaki T. 1996. Guaninerich oligonucleotide modified at the 5= terminal by dimethoxytrityl residue inhibits HIV-1 replication by specific interaction with the envelope glycoprotein. Antiviral Res. 31:137-148.
27. Chen W, Xu L, Cai L, Zheng B, Wang K, He J, Liu K. 2011. d(TGGGAG) with 5=-nucleobase-attached large hydrophobic groups as potent inhibitors for HIV-1 envelop proteins mediated cell-cell fusion. Bioorg. Med. Chem. Lett. 21:5762-5764.
28. Zhang D, Li Y, Xu L, Cheng M, Zhou Y, He J, Liu K. 2010. Hydroxylfunctionalized DNAs with different linkers and their complementary duplex stability. Nucleosides Nucleotides Nucleic Acids 29:734-747.
29. Ciminale V, Felber BK, Campbell M, Pavlakis GN. 1990. A bioassay for HIV-1 based on Env-CD4 interaction. AIDS Res. Hum. Retroviruses 6:1281-1287.
30. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
31. He Y, Liu S, Li J, Lu H, Qi Z, Liu Z, Debnath AK, Jiang S. 2008. Conserved salt bridge between the N-and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition. J. Virol. 82:11129-11139.
32. He Y, Liu S, Jing W, Lu H, Cai D, Chin DJ, Debnath AK, Kirchhoff F, Jiang S. 2007. Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. J. Biol. Chem. 282:25631-25639.
33. Chong H, Xu S, Zhang C, Nie J, Wang Y. 2009. Mutation L33M in the HR1 region of HIV-1 gp41 may play a role in T20 resistance. J. Clin. Virol. 45:255-258.
34. Yao X, Chong H, Zhang C, Waltersperger S, Wang M, Cui S, He Y. 2012. Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor Sifuvirtide. J. Biol. Chem. 287:6788-6799.
35. Cai L, Gochin M. 2007. A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type Antimicrob. Agents Chemother. 51:2388-2395.
36. Liu S, Jing W, Cheung B, Lu H, Sun J, Yan X, Niu J, Farmar J, Wu S, Jiang S. 2007. HIV gp41 C-terminal heptad repeat contains multifunctional domains relation to mechanisms of action of anti-HIV peptides. J. Biol. Chem. 282:9612-9620.
37. Qi Z, Shi W, Xue N, Pan C, Jing W, Liu K, Jiang S. 2008. Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors. J. Biol. Chem. 283:30376-30384.
38. Burnett JC, Rossi JJ. 2012. RNA-based therapeutics: current progress and future prospects. Chem. Biol. 19:60-71.